Ulrich Kohnert

This inventor holds 17 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 2 EPO patents, primarily in Biomedical Innovations. Top assignees: Boehringer Mannheim Gmbh, Hoffmann-La Roche Inc., Scil Technology Gmbh. Active years: 1993-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ulrich Kohnert. Retrieved from https://idiyas.com/inventor/ulrich-kohnert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 82.4

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 53(Granted Patents)

Company Filing History:

10 out of 1,164

Boehringer Mannheim Gmbh

patents

3 out of 5,027

Hoffmann-La Roche Inc.

Cancerforskningsfonden Af 1989

patents

5. 1 out of 489

Roche Diagnostics Gmbh

patents

where one patent can have more than one assignee

Years Active: 1993-2018

Loading Chart...

Areas of Expertise:

Thrombolytic Proteins

Osteoinductive Implants

Lipid Particles

Erythrina Caffra

Plasminogen Activators

Hydrophobic Binding Sites

Glycosylated Molecules

Pharmaceutical Preparations

Sequence Dependent Aggregation

Human Tissue Type

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10047162 - Sequence dependent aggregation (2018-08-14),

2. 9187550 - Tetranectin-apolipoprotein A-I, lipid particles containing it and its use (2015-11-17),

3. 9150641 - Sequence dependent aggregation (2015-10-06),

4. 8546334 - Device having osteoinductive and osteoconductive properties (2013-10-01),

5. 8257728 - Metal implant coated under reduced oxygen concentration with osteoinductive protein (2012-09-04),

6. 7763270 - Metal implant coated under reduced oxygen concentration with osteoinductive protein (2010-07-27),

7. 6025142 - Hydrophobic u-PAR binding site (2000-02-15),

8. 5973118 - Mutant of the Erythrina caffra type inhibitor and the use of the said (1999-10-26),

9. 5958722 - Use of recombinant inhibitor from Erythrina caffra for purifying serine (1999-09-28),

10. 5908625 - Use of the protease domain of human plasminogen activator for the (1999-06-01),

11. 5747030 - Pharmaceutical preparation containing plasminogen activators (1998-05-05),

12. 5723122 - Use of the protease domain of human plasminogen activator for the (1998-03-03),

13. 5409699 - Compositions containing glycosylated molecules having human tissue type (1995-04-25),

14. 5366730 - Stabilized compositions having human tissue type plasminogen activator (1994-11-22),

15. 5352453 - Compositions containing non-glycosylated human tissue type plasminogen (1994-10-04),

Title: Ulrich Kohnert: Innovator in Immunology and Lipid Particle Technology

Introduction

Ulrich Kohnert is a prominent inventor based in Habach, Germany, known for his significant contributions to the fields of immunology and lipid particle technology. With a total of 17 patents to his name, Kohnert has made remarkable advancements that have the potential to impact various medical applications.

Latest Patents

Among his latest patents is a method for reducing the aggregation of immunoglobulins in solution. This innovative approach involves comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence. By determining whether threonine or serine residues have been replaced by different amino acids, Kohnert's method allows for the modification of the immunoglobulin's amino acid sequence, effectively reducing aggregation. Another notable patent involves the development of lipid particles containing apolipoproteins, phosphatidylcholine, and various lipids. This invention outlines the composition of lipid particles that can include a single apolipoprotein and details the specific characteristics of the phosphatidylcholine used.

Career Highlights

Kohnert has worked with reputable companies such as Boehringer Mannheim GmbH and Scil Technology GmbH, where he has honed his expertise in the field. His work has not only contributed to the scientific community but has also paved the way for practical applications in medicine and biotechnology.

Collaborations

Throughout his career, Kohnert has collaborated with notable colleagues, including Stephan Fischer and Anne Stern. These partnerships have further enriched his research and development efforts, leading to innovative solutions in his areas of expertise.

Conclusion

Ulrich Kohnert's contributions to immunology and lipid particle technology exemplify the impact of innovative thinking in science. His patents and collaborations reflect a commitment to advancing medical research and improving therapeutic outcomes.

Profile summary based on public USPTO records.